Characteristic | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | β | P | β | P | β | P | β | P | β | P | β | P |
Delayed enhancement* | 1.32 | 0.018 | 1.82 | 0.002 | 1.89 | 0.004 | 1.78 | 0.003 | 1.71 | 0.005 | 1.88 | 0.002 |
Male gender* | Â | Â | 1.36 | 0.031 | 1.39 | 0.036 | 1.48 | 0.036 | 1.47 | 0.029 | 1.78 | 0.042 |
Age, per year** | Â | Â | Â | Â | -0.01 | 0.74 | Â | Â | Â | Â | Â | Â |
RA duration, per year** | Â | Â | Â | Â | Â | Â | 0.02 | 0.64 | Â | Â | Â | Â |
TNF inhibitor use* | Â | Â | Â | Â | Â | Â | Â | Â | -0.36 | 0.49 | Â | Â |
Framingham risk score, per% | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | -0.07 | 0.45 |
R2 (†) | 0.31 | 0.49 | 0.50 | 0.50 | 0.51 | 0.51 |